Xia N, Yang N, Shan Q, et al. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022;26:2322–36.
Article PubMed PubMed Central Google Scholar
Ogawa Y, Masugi Y, Abe T, et al. Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen. Clin Cancer Res. 2021;27:107–19.
Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18:840–6.
Article PubMed PubMed Central Google Scholar
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.
Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.
Article PubMed PubMed Central Google Scholar
Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT Imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.
Article PubMed PubMed Central Google Scholar
Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022; 49:2877–88.
Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415–23.
Article PubMed PubMed Central Google Scholar
Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using (68)Ga-DOTATOC and (68)Ga-DOTATATE. J Nucl Med. 2020;61:217–21.
Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.
Haug AR, Auernhammer CJ, Wangler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.
Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.
Ding W, Yu J, Zheng C, et al. Machine Learning-based noninvasive quantification of single-imaging session dual-tracer (18)F-FDG and (68)Ga-DOTATATE dynamic PET-CT in oncology. IEEE Trans Med Imaging. 2022;41:347–59.
Liu M, Paranjpe MD, Zhou X, et al. Sex modulates the ApoE epsilon4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959–70.
Article PubMed PubMed Central Google Scholar
Zhao Q, Chen X, Zhou Y. Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform. 2016;3:29–37.
Article PubMed PubMed Central Google Scholar
Zhou Y, Ye W, Brasic JR, Wong DF. Multi-graphical analysis of dynamic PET. Neuroimage. 2010;49:2947–57.
Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975–89.
Lang M, Spektor AM, Hielscher T, et al. Static and dynamic (68)Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264361.
Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.
Article PubMed PubMed Central Google Scholar
Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
Koopman T, Verburg N, Schuit RC, et al. Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Res. 2018;8:72.
Article PubMed PubMed Central Google Scholar
Ringheim A, Campos Neto GC, Anazodo U, et al. Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10:12.
Article PubMed PubMed Central Google Scholar
Slaets D, De Vos F. Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice. EJNMMI Res. 2013;3:66.
Article PubMed PubMed Central Google Scholar
Dendl K, Schlittenhardt J, Staudinger F, et al. The role of fibroblast activation protein ligands in oncologic PET imaging. PET Clin. 2021;16:341–51.
Coughlin JM, Slania S, Du Y, et al. (18)F-XTRA PET for enhanced imaging of the extrathalamic alpha4beta2 nicotinic acetylcholine receptor. J Nucl Med. 2018;59:1603-1608.
Iqbal R, Kramer GM, Frings V, et al. Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018;8:22.
Article PubMed PubMed Central Google Scholar
Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57.
Article PubMed PubMed Central Google Scholar
Kilvaer TK, Khanehkenari MR, Hellevik T, et al. Cancer associated fibroblasts in Stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers. PLoS ONE. 2015;10:e0134965.
留言 (0)